A study of ICP-248 for mantle cell lymphoma that has come back or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have mantle cell lymphoma that has been confirmed by a biopsy.
- You must have tried at least one treatment that included an anti-CD20 therapy, and at least one treatment that included a BTK inhibitor, and those treatments did not work or stopped working.
- You must have at least one tumor that can be measured on a scan.
- You must be well enough to be up and about for at least half the day (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral targeted therapies (ICP-248 plus orelabrutinib vs. pirtobrutinib) for people with mantle cell lymphoma that has returned or stopped responding to treatment. It aims to see which combination works better.
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Hear when a new Relapsed or Refractory Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.